Mini reviewPublished 2016
Carnitine Palmitoyltransferase Inhibitor in Diabetes
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
This review addresses progress of carnitine palmitoyltransferase targeted pharmaceuticals in diabetes and the challenges ahead. Since the discovery of carnitine palmitoyltransferase (CPT), there are lots of publications on its role in disease. The wide tissue expression, functional and biological roles have documented the physiological importance of these enzymes both in health and disease. Thus, over the years, studies have revealed essential importance of CPT1 in mammalian pathophysiology revealing CPT1 as potential drug targets. Starting from a brief description of the main functional features of CPTs, their roles in physiology and pathophysiology of different human diseases, this review describes the main classes of small molecules which are able to regulate CPT1 for diagnostic and therapeutic applications.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMolecular and Genetic Medicine
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Chen Z”
- BylineArticles whose byline prints “Cui F”
- BylineArticles whose byline prints “Meng L”
- BylineArticles whose byline prints “Chen G”
- BylineArticles whose byline prints “Li Z”
- BylineArticles whose byline prints “Xu Y”
- BylineArticles whose byline prints “Ma Z”
- BylineArticles whose byline prints “Woldegiorgis G”
